Common questions about Erelzi (FAQ)
Q: How quickly do people typically start to notice any changes after starting Erelzi?
Clinical data indicates that initial responses for the highly similar reference product have been observed in some patients within one to two weeks. However, official information suggests that the full range of benefits typically takes a longer period, generally three to six months, to develop.
Q: Is Erelzi the same kind of medication as Humira or Enbrel?
Erelzi is officially approved as a biosimilar to the reference biologic drug Enbrel. Both medicines contain etanercept and belong to the class of Tumor Necrosis Factor (TNF) inhibitors. While Humira (adalimumab) is also a TNF inhibitor, it is a chemically distinct medication from Erelzi.
Q: Are there any specific foods or supplements to avoid while on Erelzi?
According to the official product information, there are no mandatory warnings or restrictions regarding interactions between Erelzi and common foods, alcohol, or herbal supplements. It is generally necessary to disclose all supplements and other medicines to a healthcare provider.
Q: Are there any long-term effects of using Erelzi that people talk about?
Official regulatory labeling for TNF blockers, including Erelzi, includes warnings about potential risks associated with long-term use, such as serious infections and the development of malignancies (cancers). These risks are continuously tracked in long-term safety studies.
Q: How long does Erelzi stay in your system after stopping treatment?
The active ingredient in Erelzi, etanercept, has a reported half-life of approximately 70 to 102 hours (about three to four days). A drug generally requires several half-lives to be fully eliminated from the body after stopping treatment.
Q: Is Erelzi used for conditions other than inflammatory arthritis?
Yes, regulatory documents indicate that Erelzi is also indicated for the treatment of moderate to severe chronic Plaque Psoriasis in eligible adults and children. Its approved uses are not strictly limited to conditions involving the joints.
Q: Are there different strengths or formulations of Erelzi?
Official prescribing information confirms Erelzi is available as a solution for injection in two strengths: 25 mg/0.5 mL and 50 mg/mL. These are packaged in pre-filled syringes or pre-filled pens.
Q: What should I do if the Erelzi injection stings or hurts?
Injection site reactions like pain, redness, or swelling are listed in regulatory documents as a very common side effect. Official patient instructions note that allowing the pen or syringe to warm to room temperature for 15 to 30 minutes before injection may help minimize the common discomfort associated with injection site reactions.
Q: Can Erelzi cause a false positive result on a medical test?
Regulatory documents mention that rare instances of lupus-like syndrome have been reported in patients treated with etanercept. This syndrome may be associated with the detection of autoantibodies during certain medical tests.
Q: What are the guidelines regarding use of Erelzi during pregnancy?
Etanercept is known to cross the placenta. Official information states that live vaccines are generally not recommended for administration to infants for 16 weeks after birth if the mother received Erelzi during pregnancy. This is due to the potential for the drug to affect the infant's immune response.
Q: Does Erelzi need to be taken at the exact same time every day?
Erelzi is prescribed for use once weekly, and official dosing directions do not typically mandate that the injection must be administered at the exact same time of day on the scheduled weekly day.
Q: What official information is available about Erelzi's use in the elderly?
Regulatory labeling notes that patients aged 65 years and older have been documented to experience a higher incidence of infections compared to younger adults. Official labeling indicates that the risks and benefits of Erelzi should be carefully considered in this population.
Q: Are there specific symptoms that require immediate medical attention while on Erelzi?
Regulatory safety information requires that patients seek immediate medical attention if signs develop that suggest a serious condition. These include a persistent fever indicating serious infection, signs of blood problems like unusual bleeding or pallor, or symptoms of a severe allergic reaction such as difficulty breathing or facial swelling.
Q: What is the half-life of Erelzi?
According to the pharmacokinetics section of official prescribing information, the terminal half-life of Etanercept is reported to be approximately 70 to 102 hours.
Q: Can Erelzi affect dental procedures or surgery?
Due to the immunomodulating effects of Erelzi and the potential risk of infection, regulatory guidelines generally recommend that treatment be temporarily interrupted both before and after elective surgery. The decision for the exact timing of this interruption is a clinical one.
Q: Can Erelzi lead to changes in mood or anxiety?
Official adverse reaction reports have documented instances of mood changes, specifically depression, in patients treated with etanercept. The official label suggests that any new or worsening mood changes should be brought to the attention of a healthcare provider.
Q: Do I need to take any other medication alongside Erelzi?
In the treatment of Rheumatoid Arthritis, Erelzi is frequently used in combination with methotrexate. Official prescribing information states that other common medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids, may also be continued during treatment.
Q: Is it safe to travel with Erelzi?
Official storage instructions require that the medication be kept refrigerated (2 C to 8 C). The required refrigeration and temperature limits must be strictly maintained to ensure the drug’s stability and potency. If refrigeration is not possible, the drug must not be stored above 25 C for a cumulative single period exceeding 28 days.
Q: Can Erelzi be used by people with a history of cancer?
The official label includes a boxed warning concerning the development of malignancies in patients using TNF blockers. Official guidance states that for any patient with a personal history of cancer, the individual risks and benefits of using Erelzi require specialist evaluation.
Q: Are there common skin reactions besides those at the injection site?
Beyond the very common injection site reactions, the official list of adverse reactions notes that a general skin rash is reported as a common event, affecting at least 1 in 100 patients. Very rare, severe skin reactions are also documented.
Q: What is the risk of nervous system problems mentioned in Erelzi documentation?
Official labeling advises against the use of Erelzi in patients who have pre-existing or new-onset Central Nervous System (CNS) demyelinating disorders, such as multiple sclerosis. This is due to reports of demyelinating events (nerve signal damage) in patients using TNF blockers.
Q: Can Erelzi be used for Axial Spondyloarthritis?
Yes, Erelzi is specifically indicated in official documents for the treatment of Ankylosing Spondylitis (AS), which falls under the broader classification of Axial Spondyloarthritis.
Q: Is it okay to expose Erelzi to high temperatures for a short time?
Official storage instructions state that Erelzi must be protected from heat and must not be exposed to temperatures above 25 C (77 F). Exposure to high heat is prohibited as it can destroy the medicine's active protein structure.
Q: Why is it important to report a new illness while on Erelzi?
It is necessary to report a new illness immediately because Erelzi is officially contraindicated (prohibited) in patients with an active infection. Furthermore, because Erelzi affects the immune system, the risk of serious infection is heightened, and a new illness requires immediate professional evaluation.
Q: What evidence supports the use of Erelzi in patients who haven't responded to methotrexate?
Official indications for Erelzi commonly include its use in treating Rheumatoid Arthritis patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). This often positions the drug as an option following initial treatment failure with medicines like methotrexate.
Q: Does Erelzi cause weight change?
While weight change is not listed among the most common adverse effects, reports of both weight gain and weight loss have been documented as events with an unknown incidence in official clinical trial data for etanercept.
Q: Is it normal to feel extra tired when first taking Erelzi?
The official adverse reaction list includes loss of energy or weakness (asthenia) as a common event in clinical trials for the reference product. Although not always listed as 'fatigue,' this symptom indicates a feeling of being unusually tired or weak.
Q: What are the most common injection site reactions reported for Erelzi?
Injection site reactions are listed as very common in regulatory documents, with the most frequently reported types being pain, redness (erythema), swelling, and itching (pruritus) at the area of injection.
Q: How is Erelzi different from the original drug, Enbrel?
Erelzi is classified as a biosimilar to the original reference product, Enbrel. This means regulatory bodies have confirmed that there are no clinically meaningful differences between the two drugs in terms of safety, purity, or effectiveness. Differences usually relate to inactive components or the specific delivery device.
Q: Are there specific instructions for disposing of Erelzi pre-filled syringes?
Official patient instructions mandate that used pens and syringes must be placed immediately into an FDA-cleared sharps disposal container. If one is temporarily unavailable, a heavy-duty plastic household container with a tight, puncture-resistant lid may be used, and then disposed of according to local pharmaceutical waste guidelines.
Q: Can Erelzi be taken with oral medications?
Yes, Erelzi is a large protein and is not documented to be metabolized by the liver’s CYP450 enzyme system, which is responsible for interactions with many oral medications. This minimizes the risk of significant pharmacokinetic interactions with most co-administered oral drugs.
